Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Røe, Kathrine ^a,b   Bratland, Åse ^b   Vlatkovic, Ljiljana ^b   Ragnum, Harald Bull ^b,c   Saelen, Marie Grøn ^b,c   Olsen, Dag Rune ^d   Marignol, Laure ^e   Ree, Anne Hansen ^a,c  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE; STAT1 PROTEIN; STAT5A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HETEROGRAFTS; HUMANS; MALE; MICE; NEOPLASM GRADING; ORCHIECTOMY; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 84877624133     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063723     Document Type: Article

References (35)

1. So AI, Hurtado-Coll A, Gleave ME, (2003) Androgens and prostate cancer. World J Urol 21: 325-337.
2. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, et al. (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59: 572-583.
3. Dewhirst MW, Cao Y, Moeller B, (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8: 425-437.
4. Harris AL, (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
5. Marignol L, Coffey M, Lawler M, Hollywood D, (2008) Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 34: 313-327.
6. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, et al. (2009) The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 105: 8-13.
7. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, et al. (2002) Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 60: 634-639.
8. Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, et al. (2006) Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 66: 5121-5129.
9. Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick AC, et al. (2008) Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep 20: 1561-1567.
10. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
11. Sikkema AH, den Dunnen WF, Diks SH, Peppelenbosch MP, de Bont ES, (2012) Optimizing targeted cancer therapy: Towards clinical application of systems biology approaches. Crit Rev Oncol Hematol 82: 171-186.
12. Zhang J, Yang PL, Gray NS, (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
13. Hunter T, (2000) Signaling-2000 and beyond. Cell 100: 113-127.
14. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S, (2002) The protein kinase complement of the human genome. Science 298: 1912-1934.
15. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, et al. (1994) CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 54: 6049-6052.
16. Seal RL, Gordon SM, Lush MJ, Wright MW, Bruford EA, (2011) genenames.org: the HGNC resources in 2011. Nucleic Acids Res 39: D514-519.
17. Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, et al. (2010) Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys 78: 555-562.
18. Kanaya K, Kamitani T, (2003) pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion. Biochem Biophys Res Commun 306: 750-755.
19. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, et al. (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35: 403-409.
20. Ihle JN, (2001) The Stat family in cytokine signaling. Curr Opin Cell Biol 13: 211-217.
21. Hennighausen L, Robinson GW, (2008) Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 22: 711-721.
22. Liao Z, Nevalainen MT, (2011) Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer. Am J Transl Res 3: 133-138.
23. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, et al. (2003) Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278: 27287-27292.
24. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, et al. (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64: 4774-4782.
25. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, et al. (2008) Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 68: 236-248.
26. Li H, Zhang Y, Glass A, Zellweger T, Gehan E, et al. (2005) Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11: 5863-5868.
27. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, et al. (2010) Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 17: 481-493.
28. Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, et al. (2011) Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 10: 347-359.
29. Joung YH, Lee MY, Lim EJ, Kim MS, Hwang TS, et al. (2007) Hypoxia activates the IGF-1 expression through STAT5b in human HepG2 cells. Biochem Biophys Res Commun 358: 733-738.
30. Dudley AC, Thomas D, Best J, Jenkins A, (2005) A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochem J 390: 427-436.
31. Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, et al. (2003) Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 278: 40026-40031.
32. Dentelli P, Del Sorbo L, Rosso A, Molinar A, Garbarino G, et al. (1999) Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation. J Immunol 163: 2151-2159.
33. Adams RH, Alitalo K, (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8: 464-478.
34. Bergers G, Benjamin LE, (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
35. Brown JM, Wilson WR, (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.